Skip to main content

Emisphere Technologies Value Stock - Dividend - Research Selection

Emisphere Technologies

ISIN: US2913451066, WKN: 882963

Market price date: 30.11.-0001
Market price: 0,00 USD

Emisphere Technologies Fundamental data and company key figures of the share

Annual reports in USD
Key figures 30-03-2017
Cash flow
Net operating cash flow -6.813.000
Capital Expenditures -1
Free cash flow -6.813.001
Balance sheet
Total Equity -161.408.000
Liabilities & Shareholders equity 6.584.000
Income statement
Net income -10.041.000
Eps (diluted) -0,170
Diluted shares outstanding 60.687.500
Net sales/revenue 1.195.000

Fundamental ratios calculated on: 30-11--0001

Key figures 30-11--0001
Cash flow
P/C 0,00
P/FC 0,00
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization65.542.500.352,00 USD
Raw Data Source
Stock Split

Description of the company

Emisphere Technologies, Inc. is a commercial-stage pharmaceutical and drug delivery company. The Company, in partnership with pharmaceutical companies, develops new formulations of existing products, as well as new chemical entities, using its Eligen Technology. Its first prescription medical food product is oral Eligen B12. The Company utilizes its Eligen Technology to create new oral formulations of therapeutic agents. Its product pipeline includes prescription drug and medical food product candidates that are being developed in partnership or internally. Its preclinical programs focus on the development of oral formulations of potentially new treatments for diabetes and products in the areas of cardiovascular, appetite suppression and pain and on the development and potential expansion of nutritional supplement products. The Eligen Technology is an applicable oral drug delivery technology based on the use of synthetic chemical compounds known as Eligen delivery agents, or carriers.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,